Remarks

Claims 1-28 are pending in the instant application. Applicants have amended

claims 1-25 to more fully conform with U.S. practice. Applicants have cancelled

claims 26-28, without prejudice.

The specification has been amended to insert a cross reference to the related

priority applications. Applicants also respectfully request that the attached abstract be

added to the specification on a separate sheet as required.

Applicants submit herewith a Sequence Listing, identical to that which was

filed during the international stage, on one diskette and on paper totaling one page.

The required statements are also submitted herewith totaling two pages.

Applicants respectfully assert that all amendments are fairly based on the

specification, and respectfully request their entry. Applicants believe that the claims,

as amended, are in allowable form and earnestly solicited the allowance of claims 1-

25.

Respectfully submitted,

Royal N. Ronning, Jr.

Registration No.: 32,529 Attorney for Applicants

Customer No.: 22840

Amersham Biosciences Corp Patent Department 800 Centennial Avenue

Piscataway, New Jersey 08855-1327

Tel: (732) 457-8423

Fax: (732) 457-8463

T:\Pat\_Dept\IP Dept\Amendments\First Preliminary Amendment\PA\2005\PA0304 (09-20-05).doc

11